iZafe Group AB (publ) (IZAFE-B.ST)
SEK 0.21
(-0.93%)
SEK 0.21
(-0.93%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 35.92 Million SEK | 58.67% |
| 2022 | 23.62 Million SEK | -26.47% |
| 2021 | 32.13 Million SEK | -4.75% |
| 2020 | 33.73 Million SEK | -7.19% |
| 2019 | 36.35 Million SEK | 98.51% |
| 2018 | 18.31 Million SEK | 274.27% |
| 2017 | 4.89 Million SEK | -24.35% |
| 2016 | 6.46 Million SEK | 120.94% |
| 2015 | 2.92 Million SEK | -16.61% |
| 2014 | 3.51 Million SEK | -59.04% |
| 2013 | 8.57 Million SEK | 183.28% |
| 2012 | 3.02 Million SEK | -38.82% |
| 2011 | 4.94 Million SEK | -16.21% |
| 2010 | 5.9 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 714 Thousand SEK | -5.86% |
| 2024 Q1 | 4.93 Million SEK | -77.81% |
| 2024 Q2 | 4.37 Million SEK | -11.44% |
| 2023 Q1 | 5.26 Million SEK | -12.91% |
| 2023 Q3 | 4.74 Million SEK | -9.48% |
| 2023 Q2 | 5.24 Million SEK | -0.42% |
| 2023 Q4 | 22.24 Million SEK | 369.07% |
| 2023 FY | 37.49 Million SEK | 58.67% |
| 2022 Q2 | 5.24 Million SEK | -26.34% |
| 2022 FY | 23.62 Million SEK | -26.47% |
| 2022 Q3 | 5.23 Million SEK | -0.17% |
| 2022 Q1 | 7.11 Million SEK | -40.06% |
| 2022 Q4 | 6.04 Million SEK | 15.46% |
| 2021 Q2 | 7.89 Million SEK | 9.76% |
| 2021 Q4 | 11.87 Million SEK | 125.62% |
| 2021 Q1 | 7.19 Million SEK | -9.43% |
| 2021 FY | 32.13 Million SEK | -4.75% |
| 2021 Q3 | 5.26 Million SEK | -33.37% |
| 2020 Q2 | 9.37 Million SEK | -2.16% |
| 2020 Q1 | 9.57 Million SEK | -13.76% |
| 2020 Q4 | 7.94 Million SEK | 16.0% |
| 2020 FY | 33.73 Million SEK | -7.19% |
| 2020 Q3 | 6.84 Million SEK | -26.92% |
| 2019 Q2 | 9.51 Million SEK | 13.74% |
| 2019 FY | 36.35 Million SEK | 98.51% |
| 2019 Q3 | 7.37 Million SEK | -22.51% |
| 2019 Q4 | 11.1 Million SEK | 50.64% |
| 2019 Q1 | 8.36 Million SEK | 19.85% |
| 2018 Q2 | 3.97 Million SEK | 45.59% |
| 2018 FY | 18.31 Million SEK | 274.27% |
| 2018 Q1 | 2.73 Million SEK | 9.27% |
| 2018 Q3 | 4.62 Million SEK | 16.16% |
| 2018 Q4 | 6.97 Million SEK | 51.0% |
| 2017 Q2 | 800 Thousand SEK | 60.91% |
| 2017 Q3 | 1.09 Million SEK | 36.82% |
| 2017 Q4 | 2.5 Million SEK | 128.52% |
| 2017 FY | 4.89 Million SEK | -24.35% |
| 2017 Q1 | 497.16 Thousand SEK | 366.38% |
| 2016 Q3 | 839.95 Thousand SEK | -83.34% |
| 2016 FY | 6.46 Million SEK | 120.94% |
| 2016 Q2 | 5.04 Million SEK | 552.06% |
| 2016 Q1 | 773.2 Thousand SEK | 5.16% |
| 2016 Q4 | -186.63 Thousand SEK | -122.22% |
| 2015 Q4 | 735.28 Thousand SEK | 0.0% |
| 2015 Q2 | 728.54 Thousand SEK | 0.0% |
| 2015 Q1 | 728.54 Thousand SEK | -29.28% |
| 2015 FY | 2.92 Million SEK | -16.61% |
| 2015 Q3 | 735.28 Thousand SEK | 0.92% |
| 2014 FY | 3.51 Million SEK | -59.04% |
| 2014 Q4 | 1.03 Million SEK | 27.49% |
| 2014 Q2 | 808.42 Thousand SEK | -6.45% |
| 2014 Q1 | 864.18 Thousand SEK | -84.97% |
| 2014 Q3 | 808.08 Thousand SEK | -0.04% |
| 2013 Q3 | 409.04 Thousand SEK | -73.76% |
| 2013 FY | 8.57 Million SEK | 183.28% |
| 2013 Q4 | 5.75 Million SEK | 1306.1% |
| 2013 Q1 | 852.12 Thousand SEK | -25.5% |
| 2013 Q2 | 1.55 Million SEK | 82.97% |
| 2012 Q2 | 550.3 Thousand SEK | -32.76% |
| 2012 FY | 3.02 Million SEK | -38.82% |
| 2012 Q1 | 818.45 Thousand SEK | 0.0% |
| 2012 Q4 | 1.14 Million SEK | 122.76% |
| 2012 Q3 | 513.45 Thousand SEK | -6.7% |
| 2011 FY | 4.94 Million SEK | -16.21% |
| 2010 FY | 5.9 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AddLife AB (publ) | 3.01 Billion SEK | 98.808% |
| Biotage AB (publ) | 637 Million SEK | 94.36% |
| Bonesupport Holding AB (publ) | 510.93 Million SEK | 92.968% |
| Doxa AB (publ) | -259.5 Million SEK | 113.845% |
| Elekta AB (publ) | 3.39 Billion SEK | 98.94% |
| Ortivus AB (publ) | 48.45 Million SEK | 25.85% |
| Ortivus AB (publ) | 48.45 Million SEK | 25.85% |
| Q-linea AB (publ) | -43 Thousand SEK | 83653.488% |
| S2Medical AB (publ) | 20.3 Million SEK | -76.978% |
| Synsam AB (publ) | 3.76 Billion SEK | 99.045% |